In its first big move since pulling off a $306 million IPO, PRA Health Sciences is stretching out its early-stage development efforts, expanding its Phase I heft around the world.
Partners WuXi PharmaTech and AstraZeneca's MedImmune are on schedule with a rheumatoid arthritis-treating antibody designed for the Chinese market, as the country's regulators have accepted their application.
X-Chem, PPD's in-house biotech company, struck a deal with pioneering startup Navitor Pharmaceuticals, outlicensing some early-stage compounds discovered with its proprietary technology.
Months after LabCorp acquired its rival Covance, Quintiles has signed a sweeping agreement with lab testing giant Quest Diagnostics to launch a joint venture focused on clinical trials.
CRO giant Parexel International is acquiring an Indian company devoted to pharmacovigilance, looking to expand its share of the global market for managing drug safety data.
Contract drug developer Recipharm has inked a deal with Adroit Science to join forces in drug formulation.
U.K. contractor Ergomed has made Asian landfall, opening an office in Taiwan with eyes on forging traditional CRO deals and signing risk-sharing agreements with drugmakers.
Clinical trial service provider BioClinica is stretching out in the biopharma hotbed of Research Triangle Park, NC, opening a new operation to play a bigger role in drug development in the region.
When patients sign up for a clinical trial, how well do they understand the risks, requirements and restrictions that come with it? Icon, a global CRO that handles thousands of studies a year, is working with behavioral scientists at Carnegie Mellon University to study how investigators can improve the informed consent process.
Quintiles, the world's largest CRO, has reached out to startup Tute Genomics for access to its database of 8.5 billion annotations of genetic variants.
Clinical Ink, a provider of trial data software, is merging with Boston's CentrosHealth in hopes of expanding its platform for paperless studies.
PPD's Acurian subsidiary has expanded its relationship with the Society for Clinical Research Sites, a group representing thousands of trial outposts around the globe, focusing on improving patient recruitment.
Catalent is merging a few of its core business units in hopes of better focusing on getting its clients' drugs onto the market and pulling off smooth launches.
Hybrid researcher Evotec has signed a deal with microbiomics biotech Second Genome to lend out its drug discovery capabilities in hopes of crafting treatments that harness the power of the gut.
WuXi PharmaTech, China's largest CRO, is positioning itself to cash in on the fervor over new immunotherapies for cancer, planning to build a U.S. facility devoted to manufacturing the newfangled cell therapies.
The Association of Clinical Research Organizations (ACRO) assembled a group of CRO leaders to advise TransCelerate BioPharma, a nonprofit group run by the biggest names in drug development.
Canadian CRO conglomerate Altasciences struck a deal with preclinical researcher ITR Laboratories, joining forces to create a discovery-to-development offering for drugmakers.
Contract drug developer Almac has reached a milestone in its efforts to develop in-house therapeutics, taking its top prospect into Phase I trials.
Global CRO Icon is launching a new service catered to the specific needs of medical device and diagnostic developers, touting one of its recent acquisitions as key to the move.
Contract drug developer Patheon, a year removed from a $2.6 billion merger, is expanding its manufacturing footprint with another acquisition, buying up a South Carolina specialist.